The federal government just made the most consequential cannabis policy move in over 50 years — placing state-licensed medical marijuana and FDA-approved cannabis products into Schedule III, and opening an expedited path toward broader rescheduling of marijuana itself. Here’s a plain-English breakdown of what this shift actually unlocks, and what Vangst is already seeing in the talent market.
For more than five decades, marijuana sat on Schedule I of the Controlled Substances Act — categorized alongside heroin and LSD as a substance with “no accepted medical use and high potential for abuse.” Every cannabis operator, founder, HR leader, and candidate who believed in this industry has been building under the weight of that classification.
Today, that weight lifted for a meaningful slice of the industry.
The DOJ issued an immediate order placing two categories of marijuana product into Schedule III: FDA-approved cannabis products and marijuana products regulated under a qualifying state medical marijuana license. Separately, DEA has kicked off an expedited administrative hearing — starting June 29, 2026 — to consider moving marijuana itself from Schedule I to Schedule III across the board.
That’s a partial federal shift today and a real pathway to a bigger one. And while the headlines focus on regulatory mechanics, the real story is what this unlocks for the people actually building the industry: operators, investors, candidates, and the talent market that serves them all.
In plain English: state-licensed medical cannabis and FDA-approved cannabis products are no longer grouped with the most tightly restricted substances in the country. Schedule III places them alongside substances recognized to have legitimate medical applications and a moderate-to-low potential for abuse (think: ketamine, anabolic steroids, codeine-containing medications).
A few important clarifications:
For the full regulatory context, the DEA’s drug scheduling overview explains how Schedule I through Schedule V are defined and what each classification means for research, prescribing, and commerce.
Four things change the economic gravity of the industry — and all of them matter for talent.
Section 280E of the federal tax code has quietly strangled cannabis operators for decades, preventing them from deducting ordinary business expenses because they were trafficking a Schedule I substance. Effective tax rates for cannabis businesses have routinely exceeded 70% of net income as a result.
Because 280E applies to Schedule I and Schedule II substances, moving state-licensed medical product to Schedule III changes that math for medical operators immediately. They keep a meaningfully larger share of their revenue — money that can be reinvested into people, product, infrastructure, and expansion. Adult-use-only operators are not covered by today’s order and remain subject to 280E unless and until the broader rescheduling lands.
Translation: budgets that were tight for years just got more room for a big chunk of the industry.
Institutional investors, pension funds, and major banks have largely stayed on the sidelines because of Schedule I’s legal overhang. For the medical side of the industry, that wall is coming down now. For the rest, the June 29 hearing sets up the next leg. Expect a meaningful increase in:
Operators who’ve been running lean to survive the Schedule I era now have a clearer path to the capital they need to scale.
Universities, pharmaceutical companies, and product development teams have been tightly constrained in what they could study and develop. Today’s order — which explicitly prioritizes medical research — eases those restrictions significantly, clearing the way for:
This is where the next generation of cannabis roles — R&D scientists, regulatory affairs leaders, clinical operations managers, quality systems specialists — gets built.
Perhaps the most underrated effect: normalization. Federal rescheduling sends a signal to the broader business ecosystem — to landlords, insurers, service providers, advertisers, and most importantly, people — that cannabis is a legitimate industry to work in, invest in, and partner with.
That unlocks the hardest thing in cannabis: trust.
From Vangst’s seat in the cannabis talent market, here’s what we’re already seeing in the wake of the rescheduling news:
Hiring velocity is climbing. Operators who’ve been running skeleton teams now have the margin to build — especially those with medical licenses seeing immediate 280E relief. Requisitions that were frozen are reopening. [[LINK: Internal Vangst resource — 2026 cannabis hiring outlook report]]
Senior talent is taking the call. Executives who passed on cannabis roles because of federal uncertainty are finally saying yes. Expect cannabis compensation bands to catch up to other high-growth sectors as competition intensifies.
New functions are emerging. Roles that barely existed in cannabis a year ago — regulatory affairs leaders, clinical operations heads, federal compliance counsel, institutional investor relations — are now top-of-funnel searches.
Candidate confidence is surging. The best candidates evaluate industries for stability, not just opportunity. The rescheduling shift dramatically improves both sides of that equation.
Vangst was built for this moment.
We started this company because we believed the cannabis industry deserved a talent platform on par with any other high-growth sector. For years, that meant building during the hard part — helping operators hire through federal uncertainty, banking constraints, and capital droughts. We built the network, the data, and the playbooks that only a decade inside this industry can produce.
Now the tailwind matches the work.
Does Schedule III mean cannabis is federally legal? No. The DOJ’s order places state-licensed medical cannabis and FDA-approved cannabis products into Schedule III, which is a less-restricted federal category, but it is not full federal legalization. State laws still govern medical and adult-use markets.
Did adult-use cannabis get rescheduled too? Not today. Today’s immediate order covers FDA-approved cannabis products and marijuana regulated under a qualifying state medical marijuana license. A separate DEA administrative hearing — starting June 29, 2026 — is considering broader rescheduling of marijuana from Schedule I to Schedule III, which is where the adult-use question will play out.
How does rescheduling affect 280E taxes for cannabis businesses? Because 280E applies to Schedule I and Schedule II substances, medical operators whose product is now Schedule III should no longer be subject to its deduction restrictions — dramatically improving effective tax rates. Adult-use-only operators remain subject to 280E for now. Consult your tax advisor for specifics on your business. (IRS guidance on the cannabis industry.)
Will cannabis hiring increase because of Schedule III? Yes — and it already is. Vangst is seeing increased requisition volume, senior talent engagement, and the emergence of new functional roles tied to the rescheduling.
Can banks and institutional investors now work with cannabis companies? The rescheduling materially reduces the legal risk that had kept many institutional players on the sidelines, particularly for medical operators. Banking-specific legislation (e.g., SAFER Banking) will still shape the pace of capital flow, and adult-use operators remain in a tougher posture until the broader rescheduling lands.
What should cannabis employers do next? Revisit 2026 and 2027 headcount plans, build a talent pipeline now (before the competition intensifies), and align compensation bands with the new growth trajectory.
Cannabis just took its biggest step out of the most-restricted federal tier in more than 50 years. State-licensed medical operators move first; the broader industry has a real pathway behind it for the first time. What operators, employees, and patients have known for years is finally being reflected in federal policy: this is a legitimate, growing, innovation-driven industry.
More hiring. More opportunity. More scale.
If you’re building right now, this is a moment. Let’s build what comes next — together.
